S Biade1, C C Stobbe, J T Boyd, J D Chapman. 1. Department of Radiation Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA.
Abstract
PURPOSE: Previous studies indicated that cells whose chromatin is naturally compacted at the time of radiation are hypersensitive to radiation-induced killing, primarily by single-hit inactivation. Some chemicals that are known to promote chromatin compaction in interphase cells are here investigated for their radiosensitizing potential. MATERIALS AND METHODS: Okadaic acid (OA), a protein phosphatase inhibitor, fostriecin (FC), a topoisomerase II inhibitor and trichostatin A (TSA), a histone deacetylase inhibitor, were reported to promote chromatin compaction in mammalian cells. Asynchronous populations of HT-29 (human colon carcinoma) cells were exposed to various concentrations of OA, FC and TSA for various times before irradiation with various doses of Cs-137 gamma-rays and toxicity and radiosensitization were measured. Induced chromatin compaction was visualized by electron microscopy (EM). Histone 1 (H1) and histone 3 (H3) phosphorylation was measured by Western blotting, whole-cell fluorescence microscopy and confocal microscopy. RESULTS: OA and FC produced significant radiosensitization at 2 Gy after short (2 h) exposures. These chemical treatments also produced increased phosphorylation of H3 and increased chromatin compaction as measured by EM. A 2-h exposure of cells to TSA had no effect on cell radiosensitivity, histone phosphorylation or chromatin condensation. However, a 16-h exposure to TSA produced significant radiosensitization, histone phosphorylation and chromatin condensation, presumably by secondary mechanisms. CONCLUSIONS: These data are consistent with the hypothesis that compacted chromatin is a hypersensitive target for radiation killing. Furthermore, the modulation of chromatin conformation by drugs selectively in tumour cells might radiosensitize tumours whose cells are intrinsically radioresistant.
PURPOSE: Previous studies indicated that cells whose chromatin is naturally compacted at the time of radiation are hypersensitive to radiation-induced killing, primarily by single-hit inactivation. Some chemicals that are known to promote chromatin compaction in interphase cells are here investigated for their radiosensitizing potential. MATERIALS AND METHODS:Okadaic acid (OA), a protein phosphatase inhibitor, fostriecin (FC), a topoisomerase II inhibitor and trichostatin A (TSA), a histone deacetylase inhibitor, were reported to promote chromatin compaction in mammalian cells. Asynchronous populations of HT-29 (humancolon carcinoma) cells were exposed to various concentrations of OA, FC and TSA for various times before irradiation with various doses of Cs-137 gamma-rays and toxicity and radiosensitization were measured. Induced chromatin compaction was visualized by electron microscopy (EM). Histone 1 (H1) and histone 3 (H3) phosphorylation was measured by Western blotting, whole-cell fluorescence microscopy and confocal microscopy. RESULTS:OA and FC produced significant radiosensitization at 2 Gy after short (2 h) exposures. These chemical treatments also produced increased phosphorylation of H3 and increased chromatin compaction as measured by EM. A 2-h exposure of cells to TSA had no effect on cell radiosensitivity, histone phosphorylation or chromatin condensation. However, a 16-h exposure to TSA produced significant radiosensitization, histone phosphorylation and chromatin condensation, presumably by secondary mechanisms. CONCLUSIONS: These data are consistent with the hypothesis that compacted chromatin is a hypersensitive target for radiation killing. Furthermore, the modulation of chromatin conformation by drugs selectively in tumour cells might radiosensitize tumours whose cells are intrinsically radioresistant.
Authors: C Blattmann; S Oertel; M Thiemann; K J Weber; P Schmezer; O Zelezny; R Lopez Perez; A E Kulozik; J Debus; V Ehemann Journal: Strahlenther Onkol Date: 2012-01-18 Impact factor: 3.621
Authors: Zuoren Yu; Nicole E Willmarth; Jie Zhou; Sanjay Katiyar; Min Wang; Yang Liu; Peter A McCue; Andrew A Quong; Michael P Lisanti; Richard G Pestell Journal: Proc Natl Acad Sci U S A Date: 2010-04-20 Impact factor: 11.205
Authors: In Ah Kim; Jin Ho Kim; Jin Hee Shin; Il Han Kim; Jae Sung Kim; Hong-Gyun Wu; Eui Kyu Chie; Yong Ho Kim; Bo-Kyung Kim; Semie Hong; Seok Won Park; Sung Whan Ha; Charn Il Park Journal: Cancer Res Treat Date: 2005-04-30 Impact factor: 4.679
Authors: Kwanghee Kim; Julianne M Pollard; Andrew J Norris; J Tyson McDonald; Yingli Sun; Ewa Micewicz; Kelly Pettijohn; Robert Damoiseaux; Keisuke S Iwamoto; James W Sayre; Brendan D Price; Richard A Gatti; William H McBride Journal: Clin Cancer Res Date: 2009-11-17 Impact factor: 12.531
Authors: George R Blumenschein; Merrill S Kies; Vassiliki A Papadimitrakopoulou; Charles Lu; Ashok J Kumar; Justin L Ricker; Judy H Chiao; Cong Chen; Stanley R Frankel Journal: Invest New Drugs Date: 2007-10-25 Impact factor: 3.850